UA80605C2 - The indazoles having an analgesic activity - Google Patents

The indazoles having an analgesic activity Download PDF

Info

Publication number: UA80605C2
Authority: UA; Ukraine
Prior art keywords: formula; product; indazole; compound; ethanol
Prior art date: 2003-05-15

Application number

UAA200509350A

Other languages

English (en)

Ukrainian (uk)

Inventor

Maria Alessandra Alici

Nicola Cazzolla

Guido Furlotti

Angelo Guglielmotti

Lorenzo Polenzani

Original Assignee

Acraf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2004-04-23

Publication date

2007-10-10

2004-04-23 Application filed by Acraf filed Critical Acraf

2007-10-10 Publication of UA80605C2 publication Critical patent/UA80605C2/uk

Links

230000000202 analgesic effect Effects 0.000 title abstract description 8
150000002473 indoazoles Chemical class 0.000 title description 3
238000000034 method Methods 0.000 abstract description 18
239000008194 pharmaceutical composition Substances 0.000 abstract description 9
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract description 4
238000002360 preparation method Methods 0.000 abstract description 2
239000000047 product Substances 0.000 description 40
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 31
150000001875 compounds Chemical class 0.000 description 31
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
239000002253 acid Substances 0.000 description 14
208000002193 Pain Diseases 0.000 description 13
150000003839 salts Chemical class 0.000 description 13
239000002904 solvent Substances 0.000 description 13
238000001704 evaporation Methods 0.000 description 12
230000008020 evaporation Effects 0.000 description 12
239000000203 mixture Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
241000700159 Rattus Species 0.000 description 11
-1 hydroxy, amino Chemical group 0.000 description 11
208000004454 Hyperalgesia Diseases 0.000 description 10
239000011734 sodium Substances 0.000 description 10
238000005481 NMR spectroscopy Methods 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
238000000921 elemental analysis Methods 0.000 description 8
229910052739 hydrogen Inorganic materials 0.000 description 8
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
208000000094 Chronic Pain Diseases 0.000 description 7
125000003158 alcohol group Chemical group 0.000 description 7
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
229910000041 hydrogen chloride Inorganic materials 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
208000000114 Pain Threshold Diseases 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
229910052801 chlorine Inorganic materials 0.000 description 6
150000002825 nitriles Chemical class 0.000 description 6
230000036407 pain Effects 0.000 description 6
230000037040 pain threshold Effects 0.000 description 6
125000005936 piperidyl group Chemical group 0.000 description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
150000001412 amines Chemical class 0.000 description 5
230000006378 damage Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
208000004296 neuralgia Diseases 0.000 description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
238000001953 recrystallisation Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
229960001052 streptozocin Drugs 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 4
208000035154 Hyperesthesia Diseases 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
125000004356 hydroxy functional group Chemical group O* 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
208000032131 Diabetic Neuropathies Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000003412 degenerative effect Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
210000000548 hind-foot Anatomy 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
208000021722 neuropathic pain Diseases 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000000370 acceptor Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
206010053552 allodynia Diseases 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
229910052785 arsenic Inorganic materials 0.000 description 2
RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004464 hydroxyphenyl group Chemical group 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
230000003040 nociceptive effect Effects 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
230000008447 perception Effects 0.000 description 2
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
DBMHTLOVZSDLFD-UHFFFAOYSA-N piperidin-1-ylmethanamine Chemical compound NCN1CCCCC1 DBMHTLOVZSDLFD-UHFFFAOYSA-N 0.000 description 2
GSSYTYYSDFJBFK-UHFFFAOYSA-N piperidine-4-carboxamide;hydrochloride Chemical compound [Cl-].NC(=O)C1CC[NH2+]CC1 GSSYTYYSDFJBFK-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000012545 processing Methods 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000004044 response Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
LKEAXACDEKSPTH-UHFFFAOYSA-N (2-bromo-1-nitroethyl)benzene Chemical compound [O-][N+](=O)C(CBr)C1=CC=CC=C1 LKEAXACDEKSPTH-UHFFFAOYSA-N 0.000 description 1
UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 1
JOWOYBUVHGFXBS-UHFFFAOYSA-N 1-(2-phenylethyl)piperidine-4-carbonyl chloride Chemical compound C1CC(C(=O)Cl)CCN1CCC1=CC=CC=C1 JOWOYBUVHGFXBS-UHFFFAOYSA-N 0.000 description 1
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
NYLGITXFVVEBLZ-UHFFFAOYSA-N 1-methylindazol-3-amine Chemical compound C1=CC=C2N(C)N=C(N)C2=C1 NYLGITXFVVEBLZ-UHFFFAOYSA-N 0.000 description 1
OVVDFORZEGKEJM-UHFFFAOYSA-N 1-methylindazole-3-carboxylic acid Chemical compound C1=CC=C2N(C)N=C(C(O)=O)C2=C1 OVVDFORZEGKEJM-UHFFFAOYSA-N 0.000 description 1
XYBZNCPRKLFDAM-UHFFFAOYSA-N 1h-indazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)N)=NNC2=C1 XYBZNCPRKLFDAM-UHFFFAOYSA-N 0.000 description 1
BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 1
QRTAIBBOZNHRMI-UHFFFAOYSA-N 5-methyl-1h-indazole-3-carboxylic acid Chemical compound CC1=CC=C2NN=C(C(O)=O)C2=C1 QRTAIBBOZNHRMI-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101150092493 CREA gene Proteins 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
101000851593 Homo sapiens Separin Proteins 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
102100036750 Separin Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001618 algogenic effect Effects 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000004690 coupled electron pair approximation Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
XOZRFIMBWGTZSL-UHFFFAOYSA-N ethyl 1-(2-phenylethyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1CCC1=CC=CC=C1 XOZRFIMBWGTZSL-UHFFFAOYSA-N 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000012265 solid product Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000003901 trigeminal nerve Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200509350A 2003-05-15 2004-04-23 The indazoles having an analgesic activity UA80605C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT000972A ITMI20030972A1 (it)	2003-05-15	2003-05-15	Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
PCT/EP2004/004390 WO2004101548A1 (en)	2003-05-15	2004-04-23	Indazole having analgesic activity ,

Publications (1)

Publication Number	Publication Date
UA80605C2 true UA80605C2 (en)	2007-10-10

Family

ID=33446432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200509350A UA80605C2 (en)	2003-05-15	2004-04-23	The indazoles having an analgesic activity

Country Status (21)

Country	Link
US (2)	US7662836B2 (de)
EP (1)	EP1622892B1 (de)
JP (1)	JP4865559B2 (de)
KR (1)	KR101093048B1 (de)
CN (1)	CN100364988C (de)
AR (1)	AR044317A1 (de)
AT (1)	ATE501134T1 (de)
AU (1)	AU2004238449B2 (de)
CA (1)	CA2519733C (de)
DE (1)	DE602004031726D1 (de)
DK (1)	DK1622892T3 (de)
EA (1)	EA008499B1 (de)
ES (1)	ES2359242T3 (de)
GE (1)	GEP20074183B (de)
IL (1)	IL170769A (de)
IT (1)	ITMI20030972A1 (de)
MX (1)	MXPA05012297A (de)
PL (1)	PL1622892T3 (de)
SI (1)	SI1622892T1 (de)
UA (1)	UA80605C2 (de)
WO (1)	WO2004101548A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20031468A1 (it) *	2003-07-18	2005-01-19	Acraf	Farmaco ativo nel dolore neuropatico
ITMI20062230A1 (it) *	2006-11-22	2008-05-23	Acraf	Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
UA99927C2 (uk) *	2007-11-12	2012-10-25	Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А.	Медикамент, який є активним при невропатичному болі
KR101646093B1 (ko)	2008-07-29	2016-08-05	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	세로토닌 활성을 가진 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
EA024939B1 (ru)	2012-02-21	2016-11-30	Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.	1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
WO2013124169A1 (en) *	2012-02-21	2013-08-29	Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.	Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
ES2913975T3 (es)	2018-05-07	2022-06-07	Acraf	Compuestos de 1H-indazol-3-carboxamida como inhibidores de la glucógeno sintasa cinasa-3 beta

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6017931A (en)	1994-03-01	2000-01-25	Fmc Corporation	Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5654320A (en) *	1995-03-16	1997-08-05	Eli Lilly And Company	Indazolecarboxamides
WO1996038420A1 (en) *	1995-05-31	1996-12-05	Nisshin Flour Milling Co., Ltd.	Indazole derivatives having monocyclic amino group
CN1093801C (zh) *	1995-11-08	2002-11-06	东丽株式会社	直接成像型无水平版印刷版原版
WO1998007728A1 (en)	1996-08-16	1998-02-26	Smithkline Beecham Plc	PROCESS FOR THE PREPARATION OF N-[(1-nBUTYL-4-PIPERIDYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS
IT1291569B1 (it) *	1997-04-15	1999-01-11	Angelini Ricerche Spa	Indazolammidi come agenti serotoninergici
US6339087B1 (en) *	1997-08-18	2002-01-15	Syntex (U.S.A.) Llc	Cyclic amine derivatives-CCR-3 receptor antagonists
US6069152A (en) *	1997-10-07	2000-05-30	Eli Lilly And Company	5-HT4 agonists and antagonists
DE10132746A1 (de) *	2001-07-05	2003-02-06	Gruenenthal Gmbh	Substituierte 1-Phenethylpiperidinverbindungen
AU2002353186A1 (en) *	2001-12-19	2003-06-30	Smithkline Beecham P.L.C.	(1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors

2003
- 2003-05-15 IT IT000972A patent/ITMI20030972A1/it unknown
2004
- 2004-04-23 WO PCT/EP2004/004390 patent/WO2004101548A1/en not_active Ceased
- 2004-04-23 MX MXPA05012297A patent/MXPA05012297A/es active IP Right Grant
- 2004-04-23 SI SI200431647T patent/SI1622892T1/sl unknown
- 2004-04-23 AU AU2004238449A patent/AU2004238449B2/en not_active Ceased
- 2004-04-23 JP JP2006529710A patent/JP4865559B2/ja not_active Expired - Fee Related
- 2004-04-23 KR KR1020057021768A patent/KR101093048B1/ko not_active Expired - Fee Related
- 2004-04-23 DE DE602004031726T patent/DE602004031726D1/de not_active Expired - Lifetime
- 2004-04-23 PL PL04729106T patent/PL1622892T3/pl unknown
- 2004-04-23 GE GEAP20049111A patent/GEP20074183B/en unknown
- 2004-04-23 CN CNB2004800104363A patent/CN100364988C/zh not_active Expired - Fee Related
- 2004-04-23 EA EA200501818A patent/EA008499B1/ru not_active IP Right Cessation
- 2004-04-23 UA UAA200509350A patent/UA80605C2/uk unknown
- 2004-04-23 ES ES04729106T patent/ES2359242T3/es not_active Expired - Lifetime
- 2004-04-23 AT AT04729106T patent/ATE501134T1/de active
- 2004-04-23 US US10/549,930 patent/US7662836B2/en not_active Expired - Fee Related
- 2004-04-23 DK DK04729106.7T patent/DK1622892T3/da active
- 2004-04-23 EP EP04729106A patent/EP1622892B1/de not_active Expired - Lifetime
- 2004-04-23 CA CA2519733A patent/CA2519733C/en not_active Expired - Fee Related
- 2004-05-14 AR ARP040101628A patent/AR044317A1/es not_active Application Discontinuation
2005
- 2005-09-08 IL IL170769A patent/IL170769A/en not_active IP Right Cessation
2009
- 2009-12-15 US US12/638,470 patent/US8415476B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL170769A0 (en)	2009-02-11
AU2004238449A1 (en)	2004-11-25
IL170769A (en)	2012-05-31
JP2006528212A (ja)	2006-12-14
ES2359242T3 (es)	2011-05-19
EP1622892B1 (de)	2011-03-09
DE602004031726D1 (de)	2011-04-21
CN1777597A (zh)	2006-05-24
DK1622892T3 (da)	2011-06-27
EA200501818A1 (ru)	2006-06-30
CN100364988C (zh)	2008-01-30
PL1622892T3 (pl)	2011-08-31
US20100094015A1 (en)	2010-04-15
US8415476B2 (en)	2013-04-09
EA008499B1 (ru)	2007-06-29
HK1087705A1 (en)	2006-10-20
US20070010555A1 (en)	2007-01-11
WO2004101548A1 (en)	2004-11-25
JP4865559B2 (ja)	2012-02-01
GEP20074183B (en)	2007-08-10
AU2004238449B2 (en)	2010-09-02
CA2519733C (en)	2011-11-29
EP1622892A1 (de)	2006-02-08
MXPA05012297A (es)	2006-01-30
KR20060009937A (ko)	2006-02-01
CA2519733A1 (en)	2004-11-25
SI1622892T1 (sl)	2011-06-30
US7662836B2 (en)	2010-02-16
KR101093048B1 (ko)	2011-12-13
AR044317A1 (es)	2005-09-07
ATE501134T1 (de)	2011-03-15
ITMI20030972A1 (it)	2004-11-16

Publication	Publication Date	Title
AU754734B2 (en)	2002-11-21	Indazole bioisostere replacement of catechol in therapeutically active compounds
DE69404044T2 (de)	1997-10-16	Isoxazolinverbindungen als entzündungshemmende mittel
DE69407174T2 (de)	1998-07-02	Antipsychotische indazolderivate
DE69615682T2 (de)	2002-07-11	N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h-benzo[b][1,5]-diazepin-3-yl)-acetamide
CN102548409A (zh)	2012-07-04	二环芳基鞘氨醇1-磷酸酯类似物
JPH0641475B2 (ja)	1994-06-01	置換アルファアミノ酸、その製法および医薬
JP7153661B2 (ja)	2022-10-14	薬理学的に活性なアリール置換ピラゾロ［１，５－ａ］ピリミジン誘導体
JP6615896B2 (ja)	2019-12-04	アルドステロン合成酵素阻害剤
JP2001505198A (ja)	2001-04-17	Ｐｄｅ阻害剤としての置換ジヒドロベンゾフラン
JPS63297365A (ja)	1988-12-05	ジヒドロピリジン類
JPS6210508B2 (de)	1987-03-06
SU1241986A3 (ru)	1986-06-30	Способ получени производных бензамида,их гидрохлоридов или оптических изомеров
US8415476B2 (en)	2013-04-09	Indazole having analgesic activity
AU2016245418B2 (en)	2020-03-26	Novel pyridinium compounds
DE3788507T2 (de)	1994-05-19	Substituierte 1H-Imidazole.
DD279674A5 (de)	1990-06-13	Verfahren zur herstellung von hydrierten 1-benzooxacycloalkyl-pyridincarbonsaeureverbindungen
JP2011201777A (ja)	2011-10-13	光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
JPH05186460A (ja)	1993-07-27	２−（１−ピペリジル）エタノール誘導体、その製造方法およびその治療への適用
JP5868994B2 (ja)	2016-02-24	Ｋａｔｉｉ阻害剤
WO2023077049A1 (en)	2023-05-04	Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
KR20170012152A (ko)	2017-02-02	Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
WO2012065527A1 (zh)	2012-05-24	化合物及其作为l-型钙通道阻滞剂或/和乙酰胆碱酯酶抑制剂的应用
EA009077B1 (ru)	2007-10-26	Индазоламиды с аналгетической активностью
JP2018516875A (ja)	2018-06-28	環状化合物
WO2019112024A1 (ja)	2019-06-13	ピロリジン化合物